普拉替尼治疗晚期/转移性转染重排(RET)变异甲状腺癌患者:ARROW研究更新疗效与安全性数据
ARROW开放标签1/2期研究更新分析纳入晚期/转移性RET变异甲状腺癌患者,口服普拉替尼400 mg每日一次。RET突变型甲状腺髓样癌(MTC)既往接受卡博替尼和/或凡德他尼者客观缓解率(ORR)55.7%,初治者77.4%,既往治疗RET融合阳性甲状腺癌者90.9%。安全性人群175例中97.1%报告治疗相关不良事件。
要点
- RET突变型MTC既往接受卡博替尼和/或凡德他尼者ORR 55.7%,初治者ORR 77.4%。
- 既往治疗RET融合阳性甲状腺癌者ORR 90.9%,中位缓解持续时间23.6个月。
- 安全性人群175例中97.1%报告治疗相关不良事件,5.7%因此停药。
核心结论
- 在ARROW研究的更新分析中,普拉替尼在晚期/转移性RET变异甲状腺癌患者中继续显示出深度且持久的临床活性和可控的安全性。
研究设计与样本
- 开放标签1/2期ARROW研究纳入成人晚期/转移性RET突变型MTC或RET融合阳性甲状腺癌患者,口服普拉替尼400 mg每日一次。
- 主要终点为盲法独立中心审查(按RECIST v1.1)的ORR和安全性;次要终点包括缓解持续时间(DoR)、无进展生存期(PFS)和总生存期。
- 疗效在三个基线可测量病灶队列中评估:既往接受卡博替尼和/或凡德他尼(C/V)的RET突变型MTC、初治RET突变型MTC、既往治疗的RET融合阳性甲状腺癌。
- 截至2021年10月18日,可测量病灶人群包括61例既往C/V的RET突变型MTC、62例初治RET突变型MTC和22例既往接受系统治疗(包括放射性碘)的RET融合阳性甲状腺癌。
- 患者报告结局(PROs)为探索性终点。
主要发现
- ORR在既往C/V的RET突变型MTC为55.7%(95% CI:42.4-68.5),初治RET突变型MTC为77.4%(95% CI:65.0-87.1),既往治疗RET融合阳性甲状腺癌为90.9%(95% CI:70.8-98.9)。
- 中位DoR和中位PFS在既往C/V的RET突变型MTC均为25.8个月,初治RET突变型MTC均未达到,既往治疗RET融合阳性甲状腺癌分别为23.6个月和25.4个月。
- RET变异甲状腺癌安全性人群(N=175)中,97.1%报告治疗相关不良事件(TRAE),5.7%因TRAE停药,52.6%因TRAE减量,1例(0.6%)因TRAE死亡。
- 普拉替尼治疗后PROs改善或保持稳定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Rearranged during transfection (RET) alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET-altered thyroid cancer. We present an updated analysis with more patients and longer follow-up. Methods: Adult patients with advanced/metastatic RET-mutant medullary thyroid cancer (MTC) or RET fusion-positive thyroid cancer who initiated oral pralsetinib at 400 mg once daily were included. Primary endpoints were overall response rate (ORR) by blinded independent central review (per RECIST v1.1) and safety. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), and overall survival. Responses were assessed in three cohorts of patients with baseline measurable disease: patients with RET-mutant MTC who had received prior cabozantinib and/or vandetanib (C/V), treatment-naïve patients with RET-mutant MTC, and patients with previously treated RET fusion-positive thyroid cancer. Patient-reported outcomes (PROs) were an exploratory endpoint. Results: As of October 18, 2021, the measurable disease population comprised of 61 patients with RET-mutant MTC and prior C/V, 62 treatment-naïve patients with RET-mutant MTC, and 22 patients with RET fusion-positive thyroid cancer who had received prior systemic therapy, including radioactive iodine. The ORR was 55.7% [confidence interval; 95% CI: 42.4-68.5] in patients with RET-mutant MTC and prior C/V, 77.4% [95% CI: 65.0-87.1] in treatment-naïve patients with RET-mutant MTC, and 90.9% [95% CI: 70.8-98.9] in patients with previously treated RET fusion-positive thyroid cancer. Median DoR and median PFS were both 25.8 months in patients with RET-mutant MTC and prior C/V, not reached in treatment-naïve patients with RET-mutant MTC, and 23.6 and 25.4 months, respectively, in patients with previously treated RET fusion-positive thyroid cancer. In the RET-altered thyroid cancer safety population (N = 175), 97.1% of patients reported a treatment-related adverse event (TRAE); these led to discontinuation in 5.7% and dose reduction in 52.6% of patients. There was one death (0.6%) due to a TRAE. PROs improved or remained stable after pralsetinib treatment. Conclusions: In this updated analysis of the ARROW study, pralsetinib continued to show deep and durable clinical activity and a manageable safety profile in patients with advanced/metastatic RET-altered thyroid cancer. Clinical Trial Registration: NCT03037385.
引用
- Subbiah V, Hu MI, Mansfield AS, et al. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024. PMID: 38009200. doi:10.1089/thy.2023.0363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。